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ABSTRACT 
Lipid based drug delivery system such as Solid lipid nanoparticle (SLN) and Nanostructured lipid carriers (NLC) are among the most promising 
drug delivery system used in many industries such as food, pharmaceuticals and cosmetics industries. Over the last few years, new constituents 
of lipids have developed and investigated for enhancement of bioavailability. The present manuscript is an attempt on solving the concerned 
uncertainty with efficacious peroral administration of hydrophobic drugs through fabricating new lipid formulations, NLC. NLC, the second-
generation lipid carrier is usually composed of solid lipids and liquid lipids together in a system. This mixing causes depression in melting point 
of substrates and converts the mixture into solid form at body temperature and termed as NLC. NLC shows a high drug loading with minimum 
drug expulsion. The unique advantages of NLC over SLN and Lipid-drug conjugates (LDC) are increased capacity of drug loading, avoidance of 
drug expulsion. This manuscript gives detailed information on definitions and simple way of production methods, new approaches in 
formulation of NLC and it also highlights how NLC improves bioavailability of bioactive molecules through peroral route and its future 
perspective as a pharmaceutical carrier. It also gives idea about the supremacy of NLC over other lipid-based system. 
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1 Introduction 
The peroral approach of administration is the most 
preferable approach for administration of drug. The 
lipophilic drug creates problem in efficient oral delivery due 
to water solubility issues and first pass metabolism1.There 
are many different factors which decrease the degree of 
absorption of lipophilic drugs. Several lipophilic drugs are 
candidates for efflux transporters such as P-glycoprotein (P-
gp) and are also frequently predisposed to metabolism 
through cytochrome P450 (CYP) enzymes which leads to 
their significant first pass elimination and poor in 
vivo prospect. These factors are the chief reasons behind 
insufficient oral bioavailability of hydrophobic drugs2. 
Over the past decade, remarkable attempts have been made 
to improve bioavailability of bioactive molecule by 
fabricating nanotechnology based dosage form3.Among the 
various nanoparticles, lipid nanoparticles gained more 
consideration due to their distinct advantages such as highly 
stable structure, biodegradability, biocompatibility, efficient 
drug loading and sustained release properties4. 
Lipid nanoparticles are well-known to enhance oral 
absorption of drugs due to their distinct constituents. 
Basically three types of lipid nanoparticles such as Solid lipid 
nanoparticle (SLN), Nanostructured lipid carrier (NLC) and 
lipid-drug conjugates (LDC)5 are available. In this review 
recent advance in orally administered lipid nanoparticles is 
discussed6. 
Lipid-drug conjugates suffered from disadvantages such as 
particle growth, uncertain gelation tendency, abrupt 
polymeric transitions, inherent low loading rate7, 8. To 
address LDC disadvantage, SLN was developed in 1991. SLN 
have developed for the oral delivery of cyclosporine and 
Paclitaxel9. SLN was based on lipids which have solid nature 
at room temperature and generally biocompatible and 
biodegradable. SLN are small with large surface area10 but 
suffered from drawbacks such as limited drug loading, drug 
expulsion tendency11.  
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2 Nanostructured lipid carriers  
The second generation lipid carrier uses solid lipids and 
liquid lipids together. Due to this mixing a melting point 
depression is noticed, but the mixture obtained is solid at 
body temperature. NLC shows a high drug loading and 
minimum drug expulsion as compared to SLN.  
 2.1 Advantages of SLN/NLC over conventional 
particulate carriers 
 Small size permits site-specific delivery. 
 Controlled and sustained release of drug. 
 Protection of drug from biochemical degradation. 
 High drug payload. 
 Hydrophobic and hydrophilic drugs can be 
incorporated. 
 Sterilized by autoclave or by gamma radiation. 
 Lyophilizes and spray dried. 
 Nontoxic metabolites. 
 Cheap and stable. 
 Easy for large scale production12. 
2.2 Advantages of nanostructured lipid carrier  
 Provide sustained drug release.  
 Better physical stability. 
 High drug loading.  
 Useful for loading hydrophobic and hydrophilic drugs.  
 Most of lipids used are biocompatible and 
biodegradable.  
 Water based technology. 
 Economic than other polymeric or surfactant based 
delivery system.  
 Uncomplicated to validate and to get regulatory 
approval.  
 Easy for large scale production. 
2.3 Disadvantages of nanostuctured lipid carrier 
 Cause irritation and sensitizing action by few 
surfactant.  
 Cause cytotoxic effects.  
 Lack of sufficient clinical and preclinical studies13. 
3 Types of NLCs: 
Type I: Highly imperfect solid matrix: In this mixing of lipids 
causes highly disordered lipid matrix structure due to 
variation in structures of the lipids. It gives space for 
bioactive molecule to accommodate. 
Type II: Multiple oil/fat/water carriers: Generally bioactive 
molecule solubility is more in liquid lipids. Due to high liquid 
lipid concentrations a miscibility gap of solid lipids and 
liquid lipid occurs at the time of cooling which leads to phase 
separation. 
Type III: Amorphous Matrix: Solid and liquid lipids are mixed 
in such a manner that they hinder crystallization. The lipid 
matrix is in solid state, but in an amorphous form, which 
avoids crystallization and ultimately drug expulsion14. 
(Figure 1) 
 
 
 
Figure 1: Different Types of NLCs. 
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4 Composition of NLC: 
The NLC consists of solid lipid, liquid lipid, emulsifier and water. 
1. Solid Lipid (Table 1) 
Table 1: Solid lipid for formulation of NLC. 
Sr. No. Solid lipid Examples Melting point 0C 
1 Hard fats Stearic acid 67-69 
  Behenic acid 80 
  Palmitic  acid 63 
2 Hard fats Theobroma oil 35-36.5 
  Goat fat 40-50 
3 Triglycerides Trilaurin (Dynasan 112) 43-46 
  Trimyristin (Dynasan 114)  55-58 
  Tristearin (Dynasan 118) 70-73 
  Tripalmitin (Dynasan 116) 61-65 
  Tribehenate (Dynasan 122) 81-85 
  Hydrogenated Palm Oil (Dynasan P 60) 58-62 
  Hydrogenated Palm Oil (Softisan 154) 53-58 
4 Waxes  Beeswax 62-64 
  Cetyl palmitate (Precifac ATO) 51.9-55.9 
  Carnauba wax 2442 78-88 
  Apifil 59-70 
  Elfacos
 
C 26  80 
5 Partial glycerides Glyceryl Monostearate (Imwitor 900) 54-64 
  Glyceryl Monostearate (Imwitor 491) 66-77 
 
2. Liquid lipid for formulation of NLC15 (Table 2) 
Table 2: Liquid lipid for formulation of NLC. 
Sr. No. Liquid lipid Monograph name Viscosity  
mPa·s 20 0 C 
 
1 CremerCOOR MCT 
60/40 EP 
Caprylic/Capric/Triglyceride 25 to 32 
2 CremerCOOR MCT 
70/30 EP 
Caprylic/Capric/Triglyceride 
 
26 to 32 
3 Miglyol 808  Tricaprylin ~ 23 
4 Miglyol 810 N  Caprylic/Capric/Triglyceride ~ 26 
5 Miglyol 812 N  Caprylic/Capric/Triglyceride ~ 28 
6 Miglyol 818  
 
Caprylic/Capric/Linoleic 
Triglyceride 
~ 33 
7 Miglyol 8108 Caprylic/Capric Triglyceride ~ 25 
8 Oleic acid (9Z)-Octadecenoic acid 40 
9 Olive oil - 85 
10 Castor oil - 1-1.5 
11 Coconut oil - 80 
12 Soya bean oil,  - 80 
13 Palm oil - 130 
 
 
3. Surfactants 14, 15: (Table 3) 
Table 3: Surfactant for formulation of NLC. 
Surfactant HLB value  
(hydrophilic-lipophilic balance) 
Soy lecithin 4 
Egg lecithin 6.6 
Polysorbate 80 15 
Polysorbate 20 16.7 
Solutol HS 15 
Poloxamer-188 29 
Cremophor EL 12-14 
 
Different mechanisms by which NLC improves 
bioavailability of lipophilic drug: 
Direct uptake:  
NLC improves bioavailability of lipophilic drug by intestinal 
lymphatic transport. Due to utilization of triglycerides, the 
NLC may trigger the chylomicron formation and causes 
transcellular absorption. Lipophilic drug takes intestinal 
lymphatic system route and circumvents first pass effect.  
Triglyceride hydrolysis starts in the gastrointestinal tract by 
lingual lipase and gastric lipase to form triglyceride 
emulsion. This triglyceride emulsion triggers the production 
of bile salts, pancreatic juice and biliary lipids. Biliary lipids 
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adsorbed onto triglyceride emulsion surface and stabilized. 
With the action of pancreatic lipase triglyceride droplet 
forms monoglyceride and fatty acid and is absorbed by the 
enterocyte. These are then processed to form lipid core of 
chylomicron and stabilized by the addition of phospholipids 
and apolipoproteins. Then these lipoproteins are secreted 
into lamina propria and mesenteric lymph node and then to 
lymphatic circulation16, 17, 18, 19.  
Mucus adhesion: The NLC sticks to the mucus and increases 
the residence time and so there is increased release of drug 
from NLC2, 20.  
Mixed micelle formation: The lipid of NLC causes bile 
secretion in small intestine. The lipid degrades due to 
enzymes and is mixed with bile to form mixed micelle. This 
phenomenon gives enhanced solubilization of drug and 
promotes drug transport21.  
Increased permeability: NLC contains surfactants which 
causes change in intestinal permeability by different 
mechanisms. For eg. The surfactant, Poloxamer contorts the 
cell membrane and opens the tight junction of epithelial cell 
of intestine promoting paracellular transport22. It prohibit P-
glycoprotein efflux and increases NLC transport23. 
Inhibits drug degradation: NLC provides protection to 
hydrophilic and lipophilic drugs by the lipids from chemical 
and enzymatic degradation and delays in vivo metabolism24, 
25. 
6 Methods of Manufacturing of NLC  
High Pressure Homogenization Technique (HPH)- 
HPH is a most reliable technique for large-scale 
manufacturing. In HPH method lipids are pushed at very high 
pressure through a narrow gap. Due to shear stress and 
cavitations forces, breaking of particle in micron size takes 
place. HPH has two methods, hot and cold method 26, 27, 28. In 
these methods drug is dissolved in the lipid (5-10%) melted 
at 5-10º C above their melting point. 
1. Hot homogenization method- 
In this method drug and melted lipid is mixed with aqueous 
surfactant solution of same temperature by using high shear 
equipment. The obtained emulsion is stirred by using a 
piston gap homogenizer and the formed nanoemulsion is 
cooled at room temperature to form nanoparticles29. 
2. Cold homogenization method- 
In this method also drug and melted lipid is mixed with 
aqueous surfactant solution of same temperature by using 
high shear equipment. The lipid melt along with drug is 
cooled quickly by using ice or liquid nitrogen for drug 
distribution in lipid30.  
Micro-emulsion based method-  
The drug is mixed with melted lipid phase and then mixed 
with surfactant solution prepared in water at same 
temperature as that of the lipid phase. The microemulsion 
which is hot is then added to cold water. Reduction in 
temperature causes formation of nanoemulsion.  
Emulsification-Solvent Evaporation Technique-  
Lipids along with drug are dissolved in organic solvent like 
toluene or chloroform. This lipid phase added to that of 
aqueous surfactant phase. Then evaporate the solvent under 
reduced pressure. On evaporation of solvent the lipid 
precipitates causing formation of nanoparticles.  
Solvent emulsification-diffusion method- 
An o/w emulsion is formed initially consisting of organic 
phase consisting of solvents such as benzyl alcohol/ ethyl 
format/ tetrahydrofuran, mutually saturated with water to 
ensure thermodynamic equilibrium of both liquids to obtain 
nanoparticle in nanometers size31. 
Phase inversion method- 
All formulation ingredients are stirred with magnetic stirrer 
and subsequently subjected to heating and cooling cycles and 
is diluted under cooling conditions (85ºC-60ºC-85ºC-60ºC-
85ºC). Three cycles of heating and cooling from room 
temperature was applied at a rate of 4ºC/min. This causes 
the inversion of the emulsion32. 
Melting dispersion method-  
Lipid phase is prepared by adding melted lipids with drug 
solution which is prepared in an organic solvent. 
Simultaneously water phase is also heated at the same 
temperature as that of lipid phase. The oil phase is added to 
water phase and is stirred at high speed. Then cooled down 
to room temperature to obtained nanoparticles33. 
High Shear Homogenization or Ultrasonication Technique-  
Drug was added to melted solid lipid and liquid lipid. Water 
phase along with surfactant is also heated at the same 
temperature as that of lipid phase. The obtained emulsion 
was ultrasonicated using probe sonicator. In order to 
prevent recrystalization during the process, the production 
temperature kept at least 5-10ºC above the lipid melting 
point. To remove impurities emulsion should pass through 
0.45µm membrane34. 
Displacement or Injection method- 
Lipid in solvents such as ethanol, acetone or methanol is 
rapidly injected to an aqueous phase containing surfactant 
by using magnetic stirrer. An o/w emulsion is formed.  
Multiple Emulsion Technique- 
Hydrophilic drug was dissolved in aqueous solution and then 
added to melted lipid. This primary emulsion is stabilized by 
surfactants. This method applies emulsification followed by 
solvent evaporation26, 27. 
7 Applications of NLCs 
Enhancement in bioavailability and sustained release action 
are main advantages of NLC after peroral administration19. 
The lipophilic drugs can be entrapped by NLC to solve 
solubility issues. Repaglinide, a poor water soluble drug has 
low oral bioavailability35. It is most suitable to load into 
NLC36. Qi S et al prepared Repaglinide NLC with Gelucire 
50/13 as lipid excipient to dissolve the drug37.  The result 
showed significantly greater decrease of the blood glucose 
level in rats when compared to marketed Repaglinide tablets. 
Some other examples of drug loaded NLCs are showed in 
Table 4. 
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Table 4: Drugs encapsulated in NLC for oral bioavailability improvement. 
Drug 
Particle size 
(nm) 
Excipient 
Solid lipid, liquid lipid, surfactant 
Outcome Ref 
Valsartan 62±0.494  tristearin, capmul MCM EP, pluronic 
F68 (hydrophilic surfactant, span 80 
(lipophilic surfctant) 
Improved solubility and oral 
bioavailability of valsartan. 
38 
Lovastatin 235 precirol, squalene, myverol Enhanced oral bioavailability of 
lovastatin 
39 
Indomethacin 311 glyceryl monostearate , oleic acid, 
tween 80, chitosan, HTCC (coating 
material) 
improved bioavailability of 
indomethacin by coating of NLC with 
chitosan and HTCC (chitosan 
derivative) 
40 
Lovastatin 23.5±1.6  precirol ATO5, soybean lecithin, 
Labrasol, cremophor ELP 
increased in bioavailability of 
lovastatin 
41 
Curcumin and/ 
or genistein 
125 glycerol monostearate, oleic acid, 
tween 80, lecithin from soy bean,  
Developed co-loaded lipid based 
carriers for curcumin and genistein. 
42 
Berberine 160 precirol® ATO 5, oleic acid, tween 80 enhanced oral bioavailability and 
hypoglycemic effect 
43 
Raloxifene 
hydrochloride 
32.50 ± 5.12  glyceryl monostearate and capmul 
MCM C8, polyvinyl alcohol 
Improved oral bioavailability of 
poorly soluble Raloxifene 
hydrochloride. 
44 
Domperidone 30.45  trimyristin, cetyl recinoleate, tween 
80 , soy phosphatidylcholine,  
prepared stable and controlled 
release Domperidone SLN and 
Domperidone NLC  
45 
Rosuvastatin 213.26  compritol ATO 888, oleic acid, 
poloxamer 188 
enhanced bioavailability with two 
folds 
46 
Ifosfamide 223  Glycerol monooleate , oleic acid, 
poloxamer 188 
Enhanced entrapment efficiency and 
sustained released property of 
Ifosfamide. 
47 
Curcumin 150  cholesterol oleate, glycerol trioleate 
phosphatidylcholine  
enhanced bioavailability 48 
Silymarin  
 
78.87  precirol ATO-5, oleic acid, tween-80, 
Lipoid E 100 
improved bioavailability of silymarin 49 
 
8 New approaches in formulation of NLC 
Many research papers was published on NLC, many 
researcher want to improve the performance of NLC in 
terms of entrapment efficiency of drug, one attempt was 
made by a researcher Cristina Ott, the researcher evaluated 
the influence of various kinds of solid lipid matrices on 
synthesis of effective nanostructured lipid carriers with 
appropriate average diameters and physical stability. For 
this purpose two solid lipid mixtures (glyceryl monostearate 
with carnauba wax and glycerol monostearate with beeswax 
in combination with natural vegetable oils have been chosen, 
in order to create high disordered crystal lattice able to 
accommodate a complex mixture of vegetable extract (e.g. 
ivy leaves extract)50. 
9 Future perspectives 
NLCs are lipid-based system that contains solid lipid and 
liquid lipid, which causes covering of highly hydrophobic 
drugs. NLC enables protection of drug and imparts sustained 
release action of drug. Their composition includes 
surfactants, lipids that are biocompatible and approved by 
the FDA for oral administration. NLC formulation methods 
are simple and can be prepared without an organic solvent. 
It is easy to scale up the process into large batch sizes. NLC 
formulation has undergone a continuous betterment in the 
pharmaceutical and cosmetic field. These amendments 
played an important role in the application of NLCs. The 
examples described in this review through oral route clearly 
illustrate the promise of these NLCs as pharmaceutical 
carriers. Taking into consideration the increasing number of 
patented NLC-based formulations and the increasing data of 
research papers available, one can expect that the number of 
clinical trials pertaining NLCs will significantly increase in 
the near future.  
10 Conclusions  
NLC is known as smarter, latest generation of lipid 
nanoparticles with efficient drug loading and drug release 
capacity. NLC as novel systems composed of physiological 
lipid materials suitable for oral administration. NLC acts as 
sustained release and site specific drug delivery system and 
hence attracted wide attention of researchers. NLC is also 
suitable for large scale production, which will be seen in 
near future in the pharmaceutical market. 
Acknowledgements 
We gratefully acknowledge the support from Department of 
Pharmacy, Banasthali Vidyapith, Banasthali, Sanjivani 
Institute of Pharmacy and Research, Kopargaon, Institute of 
Chemical Technology, Marathwada campus, Jalna. 
Conflicts of Interest 
The authors report no conflict of interest. 
References 
1. Desai P, Date A, Patravale B, Overcoming poor oral 
bioavailability using nanoparticle formulations-opportunities 
and limitations, Drug Discovery Today Technologies, 2012; 
9:87-95. 
2. Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK, 
Nanostructured lipid carriers: An emerging platform for 
improving oral bioavailability of lipophilic drugs, International 
Journal of Pharmaceutical Investigation, 2015; 5(4):182-191. 
3. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al,  
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: 
Patil et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):758-764 
ISSN: 2250-1177                                                                                  [763]                                                                                 CODEN (USA): JDDTAO 
From Concepts to Clinic, Critical Reviews in Therapeutic Drug 
Carrier Systems, 2009; 26(6):523-580. 
4. Rajabi M, Mousa SA, Lipid Nanoparticles and their Application in 
Nanomedicine, Current Pharmaceutical Biotechnology, 2016; 
17:662-672. 
5. Muchow M, Maincent P, Muller RH, Lipid Nanoparticles with a 
Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery, Drug 
Development and Industrial Pharmacy, 2008; 34(12):1394-
1405.  
6. Das S, Chaudhury A, Recent advances in lipid nanoparticle 
formulations with solid matrix for oral drug delivery, American 
Association of Pharmaceutical Scientists Pharm Sci Tech, 2011; 
12(1):62-76. 
7. Olbrich C, Gessner A, Schroder W, Kayser O, Muller RH, Lipid–
drug conjugate nanoparticles of the hydrophilic drug 
diminazene-cytotoxicity testing and mouse serum adsorption,  
Journal of Controlled Release, 2004; 96(3):425-435. 
8. Das RJ, Baishya K, Pathak K, Recent advancement of lipid drug 
conjugate as nanoparticulate drug delivery system, 
International research journal of pharmacy, 2013; 4(1):73-78. 
9. Radtke M, Souto EB, Muller RH, Nanostructured Lipid Carriers: a 
novel generation of solid lipid drug carriers, Pharmaceutical 
Technology Europe, 2005; 17(4):45–50. 
10. Cavalli R, Caputo O, Gasco MR, Solid lipospheres of doxorubicin 
and Idarubicin, International Journal of Pharmaceutics, 1993; 
89:R9–R12. 
11. Sarangi MK, Padhi S, Solid lipid nanoparticles–a review, Journal 
of Critical Reviews, 2016; 3(3):5-12. 
12. Patel DK, Tripathy S, Nair SK, Kesharwani R, Nanostructured 
lipid carrier (NLC) a modern approach for topical delivery: A 
review. World journal of pharmacy and pharmaceutical 
sciences, 2013; 2(3):921-938. 
13. Tej K, Moin A, Gowda DV, Karunakar A, Patel NP,  Kamal SS, 
Nanostructured lipid carrier based drug delivery system, 
Journal of Chemical and Pharmaceutical Research, 2016; 
8(2):627-643. 
14. Kamble MS, Vaidya KK, Bhosale AV, Chaudhari PD, Solid lipid 
nanoparticles and Nanostructured lipid carriers- An overview, 
International Journal of Pharmaceutical and Chemical Science,  
2012; 2(4):681- 691. 
15. Anthony AA, Momoh MA and Builders PF, Lipid nanoparticulate 
drug delivery systems: A revolution in dosage form design and 
development, http://dx.doi.org/10.5772/50486. 
16. Hussain MM, Intestinal lipid absorption and lipoprotein 
formation, Current opinion in lipidology, 2014; 25(3):200-6. 
17. Seong KK, Cheol SH, Sang HK, Sun JY, Comparison between ZnO 
films grown by atomic layer deposition using H2 O or O3 as 
oxidant, Thin Solid Films, 2005; 478(1-2):103-108.  
18. http://www.vivo.colostate.edu/hbooks/pathphys/digestion/s
mallgut/absorb_lipids.html 
19. Reddy LHV, Murthy RSR, Lymphatic transport of orally 
administered drugs, Indian Journal of Experimental Biology, 
2002; 40:1097-1109. 
20. Yostawonkul J, Surassmo S, Iempridee T, Pimtong W, Suktham K, 
Sajomsang W, Gonil P, Ruktanonchai UR, Surface modification of 
nanostructure lipid carrier (NLC) by oleoyl-quaternized-
chitosan as a mucoadhesive nanocarrier, Colloids and Surfaces 
B: Biointerfaces, 2017;149:301-311. 
https://doi.org/10.1016/j.colsurfb.2016.09.049 
21. Ozgura U, Alivov YI, Liu C, Tekeb A, Reshchikov MA, A 
comprehensive review of ZnO materials and devices, Journal of 
Applied Physics, 2005; 98:041301.  
22. Banerjee D, Lao JY, Wang DZ, Huang JY, Ren ZF, Large-quantity 
free-standing ZnO nanowires, Applied Physics Letters, 2003; 83: 
2061.  
23. Karuppasamy A, Subrahmanyam A, Effect of electron 
bombardment on the properties of ZnO thin films, Materials 
Letters, 2007; 61(4-5):1256-1259. 
24. Pearton SJ, Norton DP, Ip K, Heo YW, Steiner T, Recent progress 
in processing and properties of ZnO, Progress in Materials 
Science, 2005; 50(3):293-340. 
25. Natarajan J, Karri V, Anindita D, Nanostructured Lipid Carrier 
(NLC): A Promising Drug Delivery System, Global Journal of 
Nanomedicine, 2017; 1(5):001-006. DOI: 
10.19080/GJN.2017.01.555575. 
26. Nautyal U, Kaur S, Singh R, Singh S, Devi A, Nanostructure Lipid 
Carrier (NLC): the new generation of lipid nanoparticles, Asian 
Pacific journal of health sciences, 2015; 2(2):76-93. 
27. Yang CR, Zhao XL, Hu HY, Li KX, Sun X, Li L, et al., Preparation, 
Optimization and Characteristic of Huperzine A Loaded 
Nanostructured Lipid Carriers, Chemical & pharmaceutical 
bulletin, 2010; 58(5):656-661. 
28. Oldrich C, Bakowski U, Lehr CM, et al., Cationic solid- lipid 
nanoparticles can efficiently bind and transfect plasmid DNA, 
Journal of Controlled Release, 2001; 77:345-55. 
29. Zur M ühlen A, Schwarz C, Mehnert W, Solid lipid nanoparticles 
(SLN) for controlled drug delivery – drug release and release 
mechanism, European journal of pharmaceutics and 
biopharmaceutics, 1998; 45:149-155. 
30. Gasco MR, Method for producing solid lipid microspheres 
having a narrow size distribution.1993; US Pat. No. 5250236.  
31. Chaturvedi PS, Vimal Kumar, Production Techniques of Lipid 
Nanoparticles: A Review, Research Journal of Pharmaceutical, 
Biological and Chemical Sciences. 2012; 3(3):525-541. 
32. B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, J.P. Benoit, A novel 
phase inversion-based process for the preparation of lipid 
nanocarriers, Pharmaceutical research, 2006; 19(6):875–880. 
33. Reithmeier H, Hermann J, Gopferich A, Lipid microparticles as a 
parenteral controlled release device for peptides, Journal of 
Controlled Release, 2001; 73:339-350. 
34. Eldem T, Speiser P, Hincal A, Optimization of spray-dried and 
congealed lipid microparticles and characterization of their 
surface morphology by scanning electron microscopy, 
Pharmaceutical research, 1991; 8:47-54. 
35. Jain SK, Agrawal GP, Jain NK, A novel calcium silicate based 
microspheres of repaglinide: in vivo investigations, Journal of 
Controlled Release, 2006; 113:111-116. 
36. Date AA, Vador N, Jagtap A, Nagarsenker MS, Lipid nanocarriers 
(GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a 
novelstabilizer: fabrication, characterization and evaluation for 
oral drug delivery, Nanotechnology, 2011; 22:275102 
37. Qi S, Marchaud D, Craig DQ, An investigation into the 
mechanism of dissolution rate enhancement of poorly water-
soluble drugs from spray chilled gelucire 50/13 microspheres,  
Journal of pharmaceutical sciences, 2010; 99:262-74. 
38. Patel RJ, Patel ZP, Formulation Optimization and Evaluation of 
Nanostructured Lipid Carriers Containing Valsartan,  
International Journal of Pharmaceutical Sciences and 
Nanotechnology, 2013; 6(2):2077-2086. 
39. Fang JY, Chen CC, Tsai TH, Huang ZR, Effects of lipophilic 
emulsifiers on the oral administration of lovastatin from 
nanostructured lipid carriers: Physicochemical characterization 
and pharmacokinetics, European Journal of Pharmaceutics and 
Biopharmaceutics, 2010; 74(3):474-482. 
40.  Ko S, Suh S, Choe J, Choi KO, Positively charged nanostructured 
lipid carriers and their effect on the dissolution of poorly 
soluble drugs. Molecules, 2016; 21(5):672-684. 
41. Zhou J, Zhou D, Improvement of oral bioavailability of lovastatin 
by using nanostructured lipid carriers, Drug design 
development and therapy, 2015; 9:5269-5275. 
42. Ko S, Aditya NP, Shim M, Lee I, Lee Y, Im MH, Curcumin and 
Genistein Coloaded Nanostructured Lipid Carriers: In vitro 
Digestion and Antiprostate Cancer Activity, Journal of 
agricultural and food chemistry, 2013; 61:1878-1883. 
43. Yin J, Hou Y, Yin Y, Song X, Selenium-coated nanostructured lipid 
carriers used for oral delivery of berberine to accomplish a 
synergic hypoglycemic effect, International journal of 
nanomedicine, 2017; 12:8671-8680. 
44. Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, 
Parmar GR, Nanostructured lipid carriers for oral bioavailability 
enhancement of raloxifene: Design and in vivo study, Journal of 
Advanced Research, 2016; 7(3):423-434. 
45. Thatipamula RP, Yamsani MR, Palem CR, Gannu R, Mudra gada 
S, Formulation and in vitro characterization of domperidone 
loaded solid lipid nanoparticles and nanostructured lipid 
carriers, DARU Journal of Pharmaceutical Sciences, 2011; 
19(1):23-32.  
46. Gadad AP, Tigadi SG, Mallappa P, Dandagi PM, Mastiholimath VS, 
Bolmal UB. Rosuvastatin Loaded Nanostructured Lipid Carrier: 
For Enhancement of Oral Bioavailability, Indian Journal of 
Pharmaceutical Education and Research, 2016; 50(4):605-611. 
47. Velmurugan R, Selvamuthukumar S, Development and 
optimization of ifosfamide nanostructured lipidcarriers for oral 
delivery using response surface methodology, Applied 
nanoscience, 2016; 6:159-173. 
Patil et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):758-764 
ISSN: 2250-1177                                                                                  [764]                                                                                 CODEN (USA): JDDTAO 
48. Tian C, Asghar S, Wu Y, Chen Z, Jin X, Yin L, Huang L, Ping Q, Xiao 
Y, Improving intestinal absorption and oral bioavailability of 
curcumin via taurocholic acid-modified nanostructured lipid 
carriers, International Journal of Nanomedicine, 2017; 12:7897-
7911. 
49. Shangguan M, Lu Y,  Qi J,  Han J,  Tian Z,  Xie Y,  Hu F, Yuan H, Wu 
W, Binary lipids based nanostructured lipid carriers for 
improved oral bioavailability of silymarin, Journal of 
biomaterials applications, 2013. 
https://doi.org/10.1177/0885328213485141 
50. Mitrea E, Ott C, Meghea A, New Approaches on the Synthesis of 
Effective Nanostructured Lipid Carriers, Revista De Chimie, 
2014; 65(1):50-55. doi: http://www.revistadechimie.ro
 
 
 
 
 
 
 
 
 
 
